Screener
Arcutis Biotherapeutics, Inc. ARQT Business Segments — Operating Income (Loss)
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Arcutis Biotherapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:OperatingIncomeLoss.
The source filing: Arcutis Biotherapeutics, Inc.’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 4:21 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001787306-26-000051
| Line item | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Selling, general and administrative expenses | 82,008 | 69,033 | 155,962 | 132,917 |
| Other segment expenses(1) | 6,295 | 5,509 | 12,156 | 12,694 |
| Total operating expenses | 113,432 | 96,115 | 227,919 | 186,490 |
| Operating income (loss) | 16,429 | (14,611) | 7,340 | (39,140) |
| Interest income | 2,279 | 2,076 | 4,554 | 4,613 |
| Interest expense | (3,406) | (3,029) | (7,774) | (6,011) |
| Other income (expense), net | (157) | 20 | (177) | 213 |
| Provision for income taxes | 136 | 342 | 229 | 621 |
Item 1. Financial Statements (Unaudited)
FAQ
- What is Arcutis Biotherapeutics, Inc.'s business segments — operating income (loss)?
- Arcutis Biotherapeutics, Inc. (ARQT) reported business segments — operating income (loss) of $16.43M in Q2 2026.
- How has Arcutis Biotherapeutics, Inc.'s business segments — operating income (loss) changed year-over-year?
- Arcutis Biotherapeutics, Inc.'s business segments — operating income (loss) increased by 212.4% year-over-year, from -$14.61M to $16.43M.
- What is the long-term trend for Arcutis Biotherapeutics, Inc.'s business segments — operating income (loss)?
- Over 2 years (2022 to 2024), Arcutis Biotherapeutics, Inc.'s business segments — operating income (loss) has grown at a -34.8% compound annual growth rate (CAGR), from -$301.63M to -$128.4M.
- What does business segments — operating income (loss) mean?
- Measures the profitability of the reportable segment by subtracting total operating expenses from total revenues. It serves as a key indicator of the segment's ability to generate sustainable returns from its core commercial and development activities.
Ask your AI about Arcutis Biotherapeutics, Inc.'s business segments — operating income (loss).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude